Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.
Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, Kamikubo Y, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Miyano S, Meggendorfer M, Haferlach C, Ogawa S, Adachi S.
Matsuo H, et al. Among authors: harata y.
Blood Adv. 2020 Oct 13;4(19):4623-4631. doi: 10.1182/bloodadvances.2020002457.
Blood Adv. 2020.
PMID: 32991719
Free PMC article.